🔗 Permalink

Inventor profile of:

Matthias Eder

City:

Mannheim

Country:

Germany

Published Applications:

Last publication date:

2026-01-08

Top Assignees for applications by Matthias Eder

The entities that hold a legal rights for patent applications filed by inventor Eder Matthias:

Deutsches Krebsforschungszentrum 5 Heidelberg, Germany
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG 4 Heidelberg, Germany
NOVARTIS AG 2 Basel, Switzerland
RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG 1 Heidelberg, Germany
DEUTSCHES KREBSFORSCHUNGSZENTRIUM 1 Heidelberg, Germany
Deutsches Kresbsforschungszentrum 1 Heidelberg, Germany

Recent patent applications by Eder Matthias

Matthias Eder from Mannheim, DE has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-01-08

US20260007785A1

Human necessities

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#2 | 2026-01-08

US20260007784A1

Human necessities

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#3 | 2024-11-21

US20240382631A1

Human necessities

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#4 | 2024-10-24

US20240350680A1

Human necessities

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#5 | 2021-09-16

US20210283279A1

Human necessities

Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

#6 | 2021-06-17

US20210177996A1

Human necessities

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

#7 | 2019-12-12

US20190374660A1

Human necessities

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

#8 | 2019-12-05

US20190365931A1

Human necessities

Double-labeled probe for molecular imaging and use thereof

#9 | 2019-11-07

US20190336622A1

Human necessities

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#10 | 2019-02-28

US20190060491A1

Human necessities

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

#11 | 2019-01-10

US20190008988A1

Human necessities

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

#12 | 2017-08-31

US20170246327A1

Human necessities

18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

#13 | 2016-08-11

US20160228587A1

Human necessities

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#14 | 2015-04-23

US20150110715A1

Human necessities

Double-labeled probe for molecular imaging and use thereof

InventorID:

1136161 ⎘